🚀 VC round data is live in beta, check it out!
JD Health Valuation Multiples
Discover revenue and EBITDA valuation multiples for JD Health and similar public comparables like LY Corporation, NAVER, Sigma Healthcare, Dr. Sulaiman Al Habib and more.
JD Health Overview
About JD Health
JD Health is the largest healthcare e-commerce platform in China in terms of revenue. The company offers pharmaceutical drugs and healthcare products on its platform, both as a marketplace that connects merchants to consumers and as a first-party, or 1P, direct retailer. It also offers online consultation from real life doctors and separately partners with offline pharmacies that can provide location-based 24/7 delivery as part of an omnichannel initiative to complement its core e-commerce business. Its closest competitors are Alibaba Health and Meituan for its e-commerce business. As of Dec. 31, 2024, the platform has over 200 million active annual users and over 70,000 merchants. JD Health is 67.49% owned by its parent company, JD.com.
Founded
2018
HQ
Employees
3.6K
Website
Financials (LTM)
EV
$13B
JD Health Financials
JD Health reported last 12-month revenue of $11B and EBITDA of $712M.
In the same LTM period, JD Health generated $3B in gross profit, $712M in EBITDA, and $810M in net income.
Revenue (LTM)
JD Health P&L
In the most recent fiscal year, JD Health reported revenue of $9B and EBITDA of $736M.
JD Health expects next 12-month revenue of XXX and NTM EBITDA of XXX
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue | $11B | XXX | $9B | XXX | XXX | XXX |
| Gross Profit | $3B | XXX | $2B | XXX | XXX | XXX |
| Gross Margin | 25% | XXX | 23% | XXX | XXX | XXX |
| EBITDA | $712M | XXX | $736M | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 9% | XXX | XXX | XXX |
| EBIT Margin | 6% | XXX | 3% | XXX | XXX | XXX |
| Net Profit | $810M | XXX | $610M | XXX | XXX | XXX |
| Net Margin | 7% | XXX | 7% | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
JD Health Stock Performance
JD Health has current market cap of $20B, and enterprise value of $13B.
Market Cap Evolution
JD Health's stock price is $6.19.
| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $13B | $20B | -2.9% | XXX | XXX | XXX | $0.19 |
Benchmark Trading Valuation Multiples by Industry
Sign up to access valuation multiples like growth-adjusted P/E, Rule of 40, next 12-month EV/Revenue, EBITDA multiples by industry, consensus analyst estimates and many more.
Start Free TrialJD Health Valuation Multiples
JD Health trades at 1.2x EV/Revenue multiple, and 18.3x EV/EBITDA.
EV / Revenue (LTM)
JD Health Financial Valuation Multiples
As of April 18, 2026, JD Health has market cap of $20B and EV of $13B.
Equity research analysts estimate JD Health's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
JD Health has a P/E ratio of 24.5x.
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $20B | XXX | $20B | XXX | XXX | XXX |
| EV (current) | $13B | XXX | $13B | XXX | XXX | XXX |
| EV/Revenue | 1.2x | XXX | 1.5x | XXX | XXX | XXX |
| EV/EBITDA | 18.3x | XXX | 17.7x | XXX | XXX | XXX |
| EV/EBIT | 19.5x | XXX | 60.1x | XXX | XXX | XXX |
| EV/Gross Profit | 4.6x | XXX | 6.7x | XXX | XXX | XXX |
| P/E | 24.5x | XXX | 32.5x | XXX | XXX | XXX |
| EV/FCF | 9.2x | XXX | 20.7x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Verified JD Health Valuation Multiples
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2027, based on consensus analyst estimates. Powered by FactSet and Morningstar.
JD Health Margins & Growth Rates
JD Health's revenue in the last 12 month grew by 19%.
JD Health's revenue per employee in the last FY averaged $2.4M, while opex per employee averaged $0.5M for the same period.
JD Health's rule of 40 is 26% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
JD Health's rule of X is 56% (created by Bessemer, rule of X is another metric to measure SaaS companies, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
JD Health Operational Valuation Multiples
| LTM | NTM | Last FY | FY 2026 | FY 2027 | FY 2028 | |
|---|---|---|---|---|---|---|
| Revenue Growth | 19% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Margin | 6% | XXX | 9% | XXX | XXX | XXX |
| EBITDA Growth | 20% | XXX | (8%) | XXX | XXX | XXX |
| Rule of 40 | — | XXX | 26% | XXX | XXX | XXX |
| Bessemer Rule of X | — | XXX | 56% | XXX | XXX | XXX |
| Revenue per Employee | — | XXX | $2.4M | XXX | XXX | XXX |
| Opex per Employee | — | XXX | $0.5M | XXX | XXX | XXX |
| S&M Expenses to Revenue | 5% | XXX | 5% | XXX | XXX | XXX |
| G&A Expenses to Revenue | 2% | XXX | 2% | XXX | XXX | XXX |
| R&D Expenses to Revenue | 2% | XXX | 2% | XXX | XXX | XXX |
| Opex to Revenue | — | XXX | 20% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
JD Health Public Comps
See public comps and valuation multiples for other Consumer E-commerce and Pharmacies comps.
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| LTM | 2026E | 2027E | LTM | 2026E | 2027E | |
| JD Health | XXX | XXX | XXX | XXX | XXX | XXX |
| LY Corporation | XXX | XXX | XXX | XXX | XXX | XXX |
| NAVER | XXX | XXX | XXX | XXX | XXX | XXX |
| Sigma Healthcare | XXX | XXX | XXX | XXX | XXX | XXX |
| Dr. Sulaiman Al Habib | XXX | XXX | XXX | XXX | XXX | XXX |
| Chewy | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
JD Health M&A Activity
JD Health acquired XXX companies to date.
Last acquisition by JD Health was on XXXXXXXX, XXXXX. JD Health acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Acquisitions by JD Health
| Acquired Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Get Verified M&A Valuation Multiples
Sign up to see revenue and EBITDA valuation multiples for 150K+ M&A deals.
Start Free TrialJD Health Investment Activity
JD Health invested in XXX companies to date.
JD Health made its latest investment on XXXXXXXX, XXXXX. JD Health invested in XXXXXXXX for XXX (EV/Revenue multiple of XXX).
Latest Investments by JD Health
| Company | Valuation | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXXXXX | XXX | XXX | XXX |
Benchmark 350K+ Funding Rounds and Disclosed VC Valuation Multiples
Sign up to see data on 350K+ funding rounds and disclosed revenue and EBITDA valuation multiples, from seed, through growth stage, to pre-IPO.
Start Free TrialAbout JD Health
| When was JD Health founded? | JD Health was founded in 2018. |
| Where is JD Health headquartered? | JD Health is headquartered in China. |
| How many employees does JD Health have? | As of today, JD Health has over 3K employees. |
| Who is the CEO of JD Health? | JD Health's CEO is Enlin Jin. |
| Is JD Health publicly listed? | Yes, JD Health is a public company listed on HKEX. |
| What is the stock symbol of JD Health? | JD Health trades under 06618 ticker. |
| When did JD Health go public? | JD Health went public in 2020. |
| Who are competitors of JD Health? | JD Health main competitors are LY Corporation, NAVER, Sigma Healthcare, Dr. Sulaiman Al Habib. |
| What is the current market cap of JD Health? | JD Health's current market cap is $20B. |
| What is the current revenue of JD Health? | JD Health's last 12 months revenue is $11B. |
| What is the current revenue growth of JD Health? | JD Health revenue growth (NTM/LTM) is 19%. |
| What is the current EV/Revenue multiple of JD Health? | Current revenue multiple of JD Health is 1.2x. |
| Is JD Health profitable? | Yes, JD Health is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of JD Health? | JD Health's last 12 months EBITDA is $712M. |
| What is JD Health's EBITDA margin? | JD Health's last 12 months EBITDA margin is 6%. |
| What is the current EV/EBITDA multiple of JD Health? | Current EBITDA multiple of JD Health is 18.3x. |
| What is the current FCF of JD Health? | JD Health's last 12 months FCF is $1B. |
| What is JD Health's FCF margin? | JD Health's last 12 months FCF margin is 13%. |
| What is the current EV/FCF multiple of JD Health? | Current FCF multiple of JD Health is 9.2x. |
Start Your
Free Trial Today
Try Multiples for free for 3 days. Got questions or need a demo? Schedule a call with us below.